Titre :

The impact of concomitant cytogenetic abnormalities on acute myeloid leukemia with monosomy 7 or deletion 7q after hla-matched allogeneic stem cell transplantation

Auteur(s) :

Poire, Xavier [Auteur]
Labopin, Myriam [Auteur]
Université Pierre et Marie Curie - Paris 6 [UPMC]
Polge, Emmanuelle [Auteur]
Université Pierre et Marie Curie - Paris 6 [UPMC]
Volin, Liisa [Auteur]
Finke, Jurgen [Auteur]
Ganser, Arnold [Auteur]
Blaise, Didier [Auteur]
Institut Paoli-Calmettes [IPC]
Yakoub-Agha, Ibrahim [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Beelen, Dietrich [Auteur]
Forcade, Edouard [Auteur]
Lioure, Bruno [Auteur]
Socie, Gerard [Auteur]
Niederwieser, Dietger [Auteur]
Labussiere-Wallet, Helene [Auteur]
Maertens, Johan [Auteur]
Cornelissen, Jan J. [Auteur]
Craddock, Charles [Auteur]
Mohty, Mohamad [Auteur]
Université Pierre et Marie Curie - Paris 6 [UPMC]
Esteve, Jordi [Auteur]
Nagler, Arnon [Auteur]

Titre de la revue :

American Journal of Hematology

Nom court de la revue :

Am. J. Hematol.

Numéro :

95

Pagination :

282-294

Date de publication :

2020-03

ISSN :

1096-8652

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Monosomy 7 or deletion 7q (-7/7q-) is the most frequent adverse cytogenetic features reported in acute myeloid leukemia (AML), and is a common indication for allogeneic stem cell transplantation (SCT). Nevertheless, -7/7q- ...
Lire la suite >Monosomy 7 or deletion 7q (-7/7q-) is the most frequent adverse cytogenetic features reported in acute myeloid leukemia (AML), and is a common indication for allogeneic stem cell transplantation (SCT). Nevertheless, -7/7q- occurs frequently with other high-risk cytogenetic abnormalities such as complex karyotype (CK), monosomal karyotype (MK), monosomy 5 or deletion 5q (-5/5q-), 17p abnormalities (abn(17p)) or inversion of chromosome 3 (inv(3)), the presence of which may influence the outcomes after SCT. A total of 1109 patients were allocated to this study. Two-year probability of leukemia-free survival (LFS) and overall survival (OS) were 30% and 36%, respectively. Two-year probability of non-relapse mortality (NRM) was 20%. We defined five different cytogenetic subgroups: the "-7/7q- ± CK group- designated group1," the "MK group-designated group 2," the "-5/5q- group- designated group 3," the "abn(17p) group- designated group 4" and the "inv(3) group- designated group 5." The 2-year probability of LFS in first remission was 48% for group 1, 36.4% for group 2, 28.4% for group 3, 19.1% for group 4 and 17.3% for group 5, respectively (P < .001). Multivariate analysis confirmed those significant differences across groups. Note, SCT in -7/7q- AML provides durable responses in one third of the patients. The presence of -7/7q- with or without CK in the absence of MK, abn(17p) or inv(3) is associated with a better survival after SCT. On the contrary, addition of MK, -5/5q-, abn(17p) or inv(3) identifies a sub-group of patients with poor prognosis even after SCT.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Date de dépôt :

2024-01-30T10:27:21Z
2024-01-30T15:17:48Z